ABG
NKTR icon

Ally Bridge Group’s Nektar Therapeutics NKTR Stock Holding History

Ally Bridge Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-88,977
Closed -$3.02M – 31
2022
Q4 		$3.02M Buy
88,977
+60,114
+208% +$2.91M 2.93% 16
2022
Q3 		$1.39M Buy
+28,863
New +$1.72M 0.91% 31

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ally Bridge Group's NKTR Position: Q1 2023 in Review

Ally Bridge Group sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 88,977 shares — an estimated $3.02M sold.

Ally Bridge Group first reported a position in NKTR in Q3 2022 and held it in 2 quarters. The position peaked at $3.02M in Q4 2022. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • Ally Bridge Group reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ally Bridge Group sold 88,977 Nektar Therapeutics shares in Q1 2023, an estimated $3.02M.
  • Ally Bridge Group first reported a position in Nektar Therapeutics in Q3 2022 and held it in 2 quarters.
  • Ally Bridge Group's Nektar Therapeutics position peaked at $3.02M in Q4 2022.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.